Lab Panel for Pulmonary Embolism

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Pulmonary Embolism+4 More
Lab Panel - Other
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying if a new medication is effective in treating patients with venous thromboembolism.

Eligible Conditions
  • Pulmonary Embolism
  • Deep Vein Thrombosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Pulmonary Embolism

Study Objectives

5 Primary · 5 Secondary · Reporting Duration: Participants will be asked to fill this questionnaire one month after diagnosis.

Month 6
Phosphocreatine Depletion and Recovery
Month 6
Assessment of Lymphatic flow
Month 6
Assessment for Venous Occlusion
Diagnosis to 4 weeks.
Coagulation markers
Inflammatory markers
Participants will be asked to fill out this questionnaire at one month post diagnosis.
Sleep Apnea Syndromes
Participants will be asked to fill this questionnaire one month after diagnosis.
PHQ-9 Questionnaire
Month 6
Pediatric Venous Quality of Life Questionnaire
Month 3
Exercise Intolerance
Month 6
Godin Leisure Time Activity Questionnaire

Trial Safety

Safety Progress

1 of 3

Other trials for Pulmonary Embolism

Trial Design

1 Treatment Group

Venous Thromboembolism Arm
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Lab Panel · No Placebo Group · N/A

Venous Thromboembolism ArmExperimental Group · 4 Interventions: Magnetic Resonance Imaging, Questionnaires, Bicycle Ergometry, Lab Panel · Intervention Types: Other, Behavioral, Other, Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Questionnaires
2013
Completed Phase 2
~3240

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: participants will be asked to fill this questionnaire one month after diagnosis.

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor
943 Previous Clinical Trials
606,152 Total Patients Enrolled
1 Trials studying Pulmonary Embolism
125 Patients Enrolled for Pulmonary Embolism
Maria Hanna, MDPrincipal InvestigatorUniversity of Texas Southwestern Medical Center
Ayesha Zia, MDPrincipal InvestigatorUniversity of Texas Southwestern Medical Center
1 Previous Clinical Trials
50 Total Patients Enrolled

Eligibility Criteria

Age < 65 · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a lower extremity deep venous thrombosis or pulmonary embolism.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: October 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.